Glenmark Pharmaceuticals USA to launch sodium phosphates injection

The product addresses a market with approximately $66.8 million in annual sales as of December 2025.

Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access

Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy

FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer

Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy

Synthekine teams up with Merck to test breakthrough lung cancer combo

The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line

Novo Nordisk & Vivtex team up to revolutionize oral hiologics

Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk

Eugia Pharma receives USFDA Approval for Everolimus tablets

Volta Labs unveils push-button PCR-free whole genome sequencing kit

The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform

Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy

Arcellx develops innovative immunotherapies for cancer and other incurable diseases

Lupin launches generic Brivaracetam oral solution in US to treat epilepsy

Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB

Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL

Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older